Back to top
more

DexCom (DXCM)

(Delayed Data from NSDQ)

$76.44 USD

76.44
7,419,542

-0.11 (-0.14%)

Updated Sep 17, 2025 04:00 PM ET

After-Market: $76.50 +0.06 (0.08%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.64%
2Buy17.83%
3Hold9.69%
4Sell5.29%
5Strong Sell2.54%
S&P50011.29%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

  • Value Score A
  • Growth Score A
  • Momentum Score A
  • VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

C Value B Growth C Momentum B VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 38% (93 out of 245)

Industry: Medical - Instruments

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Zacks News

Zacks Equity Research

Altair Engineering, Netgear, Fitbit, Microsoft and DexCom highlighted as Zacks Bull and Bear of the Day

by Zacks Equity Research

Altair Engineering, Netgear, Fitbit, Microsoft and DexCom highlighted as Zacks Bull and Bear of the Day

Zacks Equity Research

The Zacks Analyst Blog Highlights: JinkoSolar, Salem Media, Ciena, DexCom and Zumiez

by Zacks Equity Research

The Zacks Analyst Blog Highlights: JinkoSolar, Salem Media, Ciena, DexCom and Zumiez

Benjamin Rains headshot

3 "Internet of Things" Stocks to Buy Right Now

by Benjamin Rains

Today we've highlighted three stocks with a Zacks Rank #2 (Buy) or better that could be poised for further IoT-based growth soon.

Sweta Killa headshot

5 Top-Ranked Stocks Crushing the Market in June

by Sweta Killa

Wall Street has staged a nice comeback from the May swoon on hopes of monetary easing policies.

Zacks Equity Research

DexCom and Companion Medical Collaboration to Support CGM

by Zacks Equity Research

The collaboration enables InPen users to display real-time insulin data in Dexcom's (DXCM) CLARITY Diabetes Management Software.

Zacks Equity Research

Here's Why You Should Invest in DexCom (DXCM) Stock Now

by Zacks Equity Research

DexCom (DXCM) is gaining traction from lucrative glucose monitoring market, solid international market presence and strong product portfolio.

Zacks Equity Research

Why Is DexCom (DXCM) Down 0.4% Since Last Earnings Report?

by Zacks Equity Research

DexCom (DXCM) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Zacks Equity Research

DexCom (DXCM) Beats on Q1 Earnings, Hikes '19 Guidance

by Zacks Equity Research

DexCom's (DXCM) Q1 earnings gain from top-line growth and solid segmental performance. However, contraction in gross margin remains a headwind.

Zacks Equity Research

DexCom (DXCM) Reports Q1 Loss, Tops Revenue Estimates

by Zacks Equity Research

DexCom (DXCM) delivered earnings and revenue surprises of 70.59% and 13.82%, respectively, for the quarter ended March 2019. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

DexCom (DXCM) to Report Q1 Earnings: What's in the Offing?

by Zacks Equity Research

DexCom's (DXCM) G6 censors and lucrative collaborations are likely to drive Q1 results.

Zacks Equity Research

DexCom (DXCM) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release

by Zacks Equity Research

DexCom (DXCM) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Zacks Equity Research

Quest Diagnostics (DGX) Q1 Earnings Top Mark, Margins Down

by Zacks Equity Research

Quest Diagnostics (DGX) currently concentrates on its core diagnostic information services business and tries to maintain discipline in capital deployment.

Zacks Equity Research

Abbott (ABT) Q1 Earnings Beat Estimates, Organic Sales Solid

by Zacks Equity Research

Abbott (ABT) reports strong and consistent EPD and Medical Devices performance organically in Q1.

Zacks Equity Research

DexCom (DXCM) Stock Moves 0.35%: What You Should Know

by Zacks Equity Research

DexCom (DXCM) closed the most recent trading day at $119.30, moving +0.35% from the previous trading session.

Zacks Equity Research

DexCom (DXCM) Stock Sinks As Market Gains: What You Should Know

by Zacks Equity Research

In the latest trading session, DexCom (DXCM) closed at $116.92, marking a -0.2% move from the previous day.

Zacks Equity Research

Here's Why You Should Retain ABIOMED Stock in Your Portfolio

by Zacks Equity Research

Despite cutthroat competition in the niche markets, ABIOMED (ABMD) seems to be well-positioned for growth on strong guidance and solid product portfolio.

Zacks Equity Research

Integer Holdings Gets Positive Outlook & B+ Rating From S&P

by Zacks Equity Research

Integer (ITGR) strengthens its balance sheet by reducing its leverage ratio from 5.6X at the end of 2017 to 3.5X at 2018 end.

Zacks Equity Research

Why Veeva Systems (VEEV) is an Attractive Pick Right Now?

by Zacks Equity Research

Veeva Systems' (VEEV) strong product portfolio is likely to provide it with a competitive edge in the MedTech space.

Zacks Equity Research

Here's Why Investors Should Retain NextGen Healthcare Stock

by Zacks Equity Research

Despite aggressive rivalry in the niche space, NextGen (NXGN) will continue to benefit from strong demand for its other NextGen solutions that include Hospitals, EHR and practice management.

Zacks Equity Research

Varian Medical (VAR) Collaborates With Korea-Based Hospital

by Zacks Equity Research

Varian Medical (VAR) has seen notable developments in Asia of late.

Zacks Equity Research

Allscripts' FollowMyHealth Partners Ephraim McDowell Health

by Zacks Equity Research

Allscripts' (MDRX) FollowMyHealth is an EHR-neutral patient engagement platform that allows patients to stay connected with their physicians.

Zacks Equity Research

Fresenius Medical to Make Huge Investments, Competition Rife

by Zacks Equity Research

Fresenius Medical (FMS) is likely to make huge investments in India and China.

Zacks Equity Research

AMN Healthcare Down on Soft Locum Tenens Business, Dull View

by Zacks Equity Research

Dependence on third parties is detrimental for AMN Healthcare (AMN).

Zacks Equity Research

BD Remains Confident About LUTONIX DCB Despite FDA Letter

by Zacks Equity Research

Per the recent press release issued by BD (BDX), it seems that the company still has immense confidence on the LUTONIX DCB.

Zacks Equity Research

DexCom (DXCM) Down 11.8% Since Last Earnings Report: Can It Rebound?

by Zacks Equity Research

DexCom (DXCM) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.